<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gallant, Joel E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">COBI Can Substitute for RTV in an HIV-1 Drug Regimen</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-19</style></pages><abstract><style  face="normal" font="default" size="100%">Week 144 secondary end point results from a randomized, double-blind, double-dummy, active-controlled study involving 700 treatment-naïve HIV-1-infected patients have reaffirmed that cobicistat can be substituted for ritonavir in a drug regimen that seeks to boost the pharmacologic effect of atazanavir in combination with emtricitabine-tenofovir disoproxil fumarate.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>